Haute Capital Partners SA (BX Swiss: HAUTE) announces that, at the Annual General Meeting held today in Bern, shareholders approved by an absolute majority all the resolutions put to the vote, including the 2025 financial statements and the re-election of the current members of the Board of Directors.

Swiss-German biotech company completes candidate selection for its MAGE-A4 program and secures CHF 18 million in Series A financing.

2025 marked a structural inflection point. The Group accelerated its transition toward a Swiss-focused private equity investment entity. With a stronger balance sheet, Haute enters 2026 with improved earnings visibility and a clearer long-term growth trajectory.

Haute Capital Partners SA participates in the transaction as a direct investor and strategic partner of the round.